 VANCOUVER, British Columbia--BUSINESS WIRE--Zymeworks Inc. NYSE:ZYME, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab formerly ZW25 monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer BTC. Zymeworks will receive a US10 million payment under its collaboration with BeiG 